Tema ETFs LLC Increases Stock Position in Amgen Inc. $AMGN

Tema ETFs LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 14.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,231 shares of the medical research company’s stock after purchasing an additional 3,326 shares during the quarter. Tema ETFs LLC’s holdings in Amgen were worth $9,499,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Anfield Capital Management LLC grew its holdings in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the last quarter. Dogwood Wealth Management LLC lifted its position in Amgen by 275.0% during the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the period. Tower View Wealth Management LLC lifted its position in Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after acquiring an additional 63 shares during the period. Manning & Napier Advisors LLC grew its stake in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares during the last quarter. Finally, Ares Financial Consulting LLC acquired a new position in shares of Amgen in the fourth quarter valued at approximately $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Down 0.7%

Amgen stock opened at $414.30 on Wednesday. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $421.79. The firm has a market capitalization of $223.98 billion, a price-to-earnings ratio of 25.75, a price-to-earnings-growth ratio of 3.88 and a beta of 0.41. The stock’s fifty day moving average is $366.26 and its two-hundred day moving average is $357.53. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm’s revenue was up 9.5% on a year-over-year basis. During the same period in the prior year, the company earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Analysts predict that Amgen Inc. will post 22.78 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Friday, August 21st. Amgen’s payout ratio is currently 62.65%.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the sale, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the subject of several recent research reports. The Goldman Sachs Group set a $389.00 price target on Amgen in a report on Friday, June 5th. Oppenheimer raised their target price on shares of Amgen from $400.00 to $450.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. UBS Group boosted their price target on shares of Amgen from $420.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Truist Financial lifted their price objective on Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average target price of $371.68.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.